Table S1. Catecholamine usage within 12 h of starting PMX-DHP and the doses administered

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | 0 h (Baseline) | 2 h | 5 h | 8 h | 12 h |
| Dopamine |  |  |  |  |  |
| Usage, N (%) |  |  |  |  |  |
| PMX-DHP-12h (n = 16) | 10 (63) | 10 (63) | 10 (63) | 10 (63) | 8 (50) |
| PMX-DHP-2h (n = 7) | 5 (71) | 5 (71) | 5 (71) | 5 (71) | 5 (71) |
| Dose, µg/kg/min, median [IQR] |  |  |  |  |  |
| PMX-DHP-12h (n = 16) | 4.1 [0 – 6.9] | 4.1 [0 – 7.3] | 3.3 [0 – 7.1] | 2.6 [0 – 7.1] | 1.6 [0 – 6.5] |
| PMX-DHP-2h (n = 7) | 7.1 [0 – 10.0] | 7.1 [0 – 10.0] | 4.8 [0 – 10.0] | 4.8 [0 – 10.0] | 4.8 [0 – 10.0] |
| Dobutamine |  |  |  |  |  |
| Usage, N (%) |  |  |  |  |  |
| PMX-DHP-12h (n = 16) | 4 (25) | 4 (25) | 4 (25) | 4 (25) | 4 (25) |
| PMX-DHP-2h (n = 7) | 2 (29) | 2 (29) | 2 (29) | 2 (29) | 2 (29) |
| Dose, µg/kg/min, median [IQR] |  |  |  |  |  |
| PMX-DHP-12h (n = 16) | 0 [0 – 1.5] | 0 [0 – 1.5] | 0 [0 – 1.5] | 0 [0 – 1.5] | 0 [0 – 1.5] |
| PMX-DHP-2h (n = 7) | 0 [0 – 10.0] | 0 [0 – 10.0] | 0 [0 – 8.0] | 0 [0 – 6.0] | 0 [0 – 4.0] |
| Adrenaline |  |  |  |  |  |
| Usage, N (%) |  |  |  |  |  |
| PMX-DHP-12h (n = 16) | 1 (6) | 1 (6) | 1 (6) | 1 (6) | 1 (6) |
| PMX-DHP-2h (n = 7) | 2 (29) | 1 (14) | 1 (14) | 1 (14) | 1 (14) |
| Dose, µg/kg/min, median [IQR] |  |  |  |  |  |
| PMX-DHP-12h (n = 16) | 0 [0 – 0] | 0 [0 – 0] | 0 [0 – 0] | 0 [0 – 0] | 0 [0 – 0] |
| PMX-DHP-2h (n = 7) | 0 [0 – 0.15] | 0 [0 – 0] | 0 [0 – 0] | 0 [0 – 0] | 0 [0 – 0] |
| Noradrenaline |  |  |  |  |  |
| Usage, N (%) |  |  |  |  |  |
| PMX-DHP-12h (n = 16) | 16 (100) | 16 (100) | 16 (100) | 15 (94) | 13 (81) |
| PMX-DHP-2h (n = 7) | 7 (100) | 7 (100) | 7 (100) | 7 (100) | 7 (100) |
| Dose, µg/kg/min, median [IQR] |  |  |  |  |  |
| PMX-DHP-12h (n = 16) | 0.28 [0.16 – 0.40] | 0.29 [0.16 – 0.40] | 0.25 [0.16 – 0.34] | 0.20 [0.11 – 0.25] | 0.18 [0.06 – 0.25] |
| PMX-DHP-2h (n = 7) | 0.30 [0.30 – 0.40] | 0.30 [0.30 – 0.40] | 0.30 [0.30 – 0.40] | 0.30 [0.20 – 0.40] | 0.30 [0.15 – 0.40] |

Phenylephrine was administered in no cases.

PMX-DHP-2h: polymyxin direct hemoperfusion for two hours, PMX-DHP-12h: polymyxin direct hemoperfusion for twelve hours, IQR: interquartile range